Get the Stockscreener App
30.85
0.24%
0.1609
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $30.85, with a volume of 172.73K.
It is up +0.24% in the last 24 hours and down -9.25% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
See More
Previous Close:
$30.69
Open:
$30.43
24h Volume:
172.73K
Relative Volume:
0.19
Market Cap:
$1.60B
Revenue:
$225.21M
Net Income/Loss:
$-15.70M
P/E Ratio:
-91.11
EPS:
-0.3386
Net Cash Flow:
$-4.78M
1W Performance:
+5.29%
1M Performance:
-9.25%
6M Performance:
+83.12%
1Y Performance:
+76.61%
1-Day Range:
$30.01
$30.85
1-Week Range:
$27.54
$30.85
52-Week Range:
$9.215
$36.00
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
30.85 | 1.59B | 225.21M | -15.70M | -4.78M | -0.3386 |
|
ABT
Abbott Laboratories
|
110.21 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
343.37 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.00 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.86 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.64 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Wells Fargo | Overweight |
| Dec-01-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Lake Street | Buy |
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
Axogen at Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+ - MarketBeat
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors? - simplywall.st
AxoGen at Leerink Conference: Strategic Growth and Market Expansion - Investing.com India
Chipmakers Recap: Is Axogen Inc in a bullish channel2026 Analyst Calls & Accurate Entry/Exit Alerts - baoquankhu1.vn
Royce & Associates LP Purchases New Shares in AxoGen, Inc. $AXGN - MarketBeat
(AXGN) Risk Channels and Responsive Allocation - Stock Traders Daily
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption - National Today
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference - MarketBeat
AxoGen, Inc. $AXGN Shares Acquired by First Eagle Investment Management LLC - MarketBeat
AXGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Roubaix Capital LLC Purchases New Position in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN) CMO granted 23,000 RSUs and adjusts share holdings - Stock Titan
Axogen (AXGN) innovation chief reports stock awards and tax-share withholding - Stock Titan
Axogen (NASDAQ: AXGN) EVP reports RSU vesting and tax share withholding - Stock Titan
AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Axogen, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Axogen, Inc. Rings the Opening Bell - Nasdaq
Why Axogen (AXGN) Is Down 10.1% After Avance FDA Win and 2026 Guidance Shift - simplywall.st
AxoGen Set to Announce Q4 Earnings on February 24 - Intellectia AI
AXGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Downgrades AxoGen (NASDAQ:AXGN) to Buy - MarketBeat
AxoGen, Inc. (AXGN) Stock Analysis: Strong Buy Ratings Signal A 22.88% Upside Potential - DirectorsTalk Interviews
Equity awards and tax share withholding for Axogen (NASDAQ: AXGN) CFO - Stock Titan
Axogen (NASDAQ: AXGN) CEO granted 98,000 RSUs vesting through 2030 - Stock Titan
Axogen (AXGN) Valuation Check After FDA Avance Approval And New 2026 Growth Targets - Sahm
A Look At Axogen (AXGN) Valuation After Recent Share Price Pullback And BLA Expectations - Yahoo Finance
AxoGen Posts Strong Growth and Raises Capital With Offering - The Globe and Mail
Citizens reiterates AxoGen stock rating on strong quarterly revenue By Investing.com - Investing.com Nigeria
AxoGen, Inc. (NASDAQ:AXGN) Q4 2025 Earnings Call Transcript - Insider Monkey
axogen Q4 2025 slides: 21% revenue surge, stock tumbles on costs - Investing.com India
Citizens reiterates AxoGen stock rating on strong quarterly revenue - Investing.com
Axogen Q4: EPS Miss Amid Biologics Transition (NASDAQ:AXGN) - Seeking Alpha
Axogen Inc earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Decoding Axogen Inc (AXGN): A Strategic SWOT Insight - GuruFocus
AxoGen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
axogen Q4 2025 slides: 21% revenue surge, stock tumbles on costs By Investing.com - Investing.com South Africa
Axogen (AXGN) CFO receives 17,500 RSUs and 17,500 shares, 6,704 withheld for taxes - Stock Titan
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Axogen (AXGN) Q4 2025 Earnings Call Transcript - Nasdaq
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock - The Globe and Mail
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
CEO Moves: Is Axogen Inc a play on infrastructure spendingMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
AxoGen Q4 2025 Earnings Call Transcript - MarketBeat
Axogen, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AXGN) 2026-02-24 - Seeking Alpha
AxoGen Q4 Earnings Call Highlights - MarketBeat
AXGN Stock: Citizens Maintains Rating, Raises Price Target to $4 - GuruFocus
AxoGen (NASDAQ:AXGN) Shares Gap Down on Disappointing Earnings - MarketBeat
AXGN: 2025 saw 20% revenue growth, FDA BLA approval, and strong outlook for 2026 with 18%+ growth - TradingView
Earnings call transcript: AxoGen Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com India
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):